There are over 30 million chronic wounds that require treatment by professionals. Modern lifestyle, obesity and high incidents of diabetes are the main reasons for a strong upward trend. Considering that the average healing time of a chronic wound is estimated at 10 months it becomes very apparent why advanced wound care is such a burden on the health care system.
Main factors for supporting wound healing incl
- Exudate management and provision of moist wound environment
- Prevention and elimination of infections
- Removal of necrotic tissue
- Cell growth promotion
Through development of novel advanced materials BASF Future Business is committed to introduce products under the ENLUXTRA® trademark that make a difference in the healing of chronic wounds.
Introducing the novel Humifiber™ Technology presents a real break-through in advanced wound care. This new technology allows to address the needs of dry and wet wounds at the same time. This represents a paradigm shift with a significant impact on wound healing.
A clinical study at the reputable Dr. R Wolcott Wound Care Clinic in Lubbock TX (USA) confirmed exceptional performance:
“The unique property to sequester large amounts of exudate or conversely be a moisture donor for a dry wound, allowing the dressing to be used throughout the healing of a wound dressing also showed very good properties with regard to preservation of peri-wound skin
Our conclusion is that this dressing is effective on all types of wounds with minimal to heavy exudation. It also seemed that this dressing minimized formation of biofilms thus reducing the need for debridement….”
This proprietary technology allows caregivers to prepare a highly effective yet totally safe wound cleanser. The technology is based on the controlled release of chlorine dioxide, known as a highly effective antimicrobial. An in-vivo study confirmed very fast kill rates for most microorganisms including eradication of biofilm while exhibiting very good tissue compatibility.
BASF is also leveraging its expertise in developing and manufacturing peptides and other bioresorbable materials suitable for the use as wound fillers and cell scaffolds.
